More info…
Shares of Orexigen Therapeutics Inc. surged Thursday after the drugmaker said it signed a $1 billion co-development agreement for its experimental obesity drug Contrave with Takeda Pharmaceuticals.
Orexigen signs $1 billion obesity drug deal